Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Melphalan for T-Cell Tolerization in Reduced Intensity HSCT
NCT01350258Phase 2Terminated
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center
- Start
- Apr 2011
- Primary completion
- May 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of melphalan in acute leukemia, myelodysplastic syndrome (MDS), Hodgkin lymphoma (HL) and 3 more, sponsored by Sidney Kimmel Comprehensive Cancer Center. Primary endpoints: Defined Dose of Melphalan and Non-Relapse Mortality. Started Apr 2011; status: terminated.
02
Drugs
melphalan
03
Conditions
acute leukemiamyelodysplastic syndrome (MDS)Hodgkin lymphoma (HL)non-Hodgkin lymphoma (NHL)multiple myeloma (MM)
Beyond the preview
Go deeper on NCT01350258.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01350258.